肌醇2,4,6-三磷酸酯 | 114418-88-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 肌醇2,4,6-三磷酸酯
• 英文名称: Myo-inositol 1,3,5-trisphosphate
• 英文别名: (2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl) dihydrogen phosphate
• CAS: 114418-88-1
• 化学式: C₆H₁₅O₁₅P₃
• 分子量: 420.1
• InChiKey: RURWIJNHQMXJDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  261
• 氢给体数：
  9
• 氢受体数：
  15

反应信息

• 作为产物：
  描述：

  2,4,6-tri-O-benzyl-myo-inositol 1,3,5-tris(dibenzyl-phosphate) 以34%的产率得到
  参考文献：
  名称：

  VACCA, JOSEPH P.;SOIMS, S. JANE DE;HUFF, JOEL R.;BILLINGTON, DAVID C.;BAK+, TETRAHEDRON, 45,(1989) N7, C. 5679-5702

  摘要：

  DOI：

文献信息

• PAK 2: modulators of lymphocyte activation
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20020142325A1

  公开（公告）日：2002-10-03

  The present invention relates to regulation of lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding PAK2, which is involved in modulation of lymphocyte activation. The invention further relates to methods for identifying and using agents, including small organic molecules, peptides, circular peptides, antibodies, lipids, antisense nucleic acids, and ribozymes, that modulate lymphocyte activation via modulation of PAK2; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression.

  本发明涉及淋巴细胞活化的调节。更具体地说，本发明涉及编码 PAK2 的核酸，PAK2 参与淋巴细胞活化的调节。本发明进一步涉及鉴定和使用通过调节 PAK2 来调节淋巴细胞活化的制剂（包括有机小分子、肽、环肽、抗体、脂质、反义核酸和核酶）的方法；以及表达谱和组合物在与淋巴细胞活化和抑制有关的诊断和治疗中的应用。
• TRAC1: modulators of lymphocyte activation
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20020146747A1

  公开（公告）日：2002-10-10

  The present invention relates to regulation of lymphocyte activation. More particularly, the present invention is directed to nucleic acids encoding TRAC1, which is involved in modulation of lymphocyte activation. The invention further relates to methods for identifying and using agents, including small organic molecules, peptides, circular peptides, antibodies, lipids, antisense nucleic acids, and ribozymes, that modulate lymphocyte activation via modulation of TRAC1; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression.

  本发明涉及淋巴细胞活化的调节。更具体地说，本发明涉及编码 TRAC1 的核酸，TRAC1 参与淋巴细胞活化的调节。本发明进一步涉及鉴定和使用通过调节 TRAC1 来调节淋巴细胞活化的制剂的方法，这些制剂包括有机小分子、肽、环肽、抗体、脂质、反义核酸和核酶；本发明还涉及在与淋巴细胞活化和抑制有关的诊断和治疗中使用表达谱和组合物的方法。
• EDG: modulators of lymphocyte activation and migration
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20020155512A1

  公开（公告）日：2002-10-24

  The present invention relates to regulation of lymphocyte activation and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.

  本发明涉及淋巴细胞活化和迁移的调节。更具体地说，本发明涉及编码 EDG 家族 GPCR 蛋白的核酸，如 EDG-1、2、3、4、5、6、7 或 8，它们参与淋巴细胞活化和迁移的调节。本发明进一步涉及鉴定和使用通过调节 EDG GPCR 和 EDG 相关信号转导来调节淋巴细胞活化或迁移的制剂（包括有机小分子、抗体、肽、环肽、核酸、反义核酸、鞘脂类似物和核酶）的方法；以及表达谱和组合物在与淋巴细胞活化和抑制以及淋巴细胞迁移相关的诊断和治疗中的应用。
• VACCA, JOSEPH P.;SOIMS, S. JANE DE;HUFF, JOEL R.;BILLINGTON, DAVID C.;BAK+, TETRAHEDRON, 45,(1989) N7, C. 5679-5702
  作者：VACCA, JOSEPH P.、SOIMS, S. JANE DE、HUFF, JOEL R.、BILLINGTON, DAVID C.、BAK+

  DOI：——

  日期：——
• Methods and compositions for screening for altered cellular phenotypes
  申请人：——

  公开号：US20030022196A1

  公开（公告）日：2003-01-30

  The invention relates to methods and compositions useful for screening for altered cellular phenotypes using an inducible expression system to enrich for and detect the altered phenotypes and, more particularly, relates to screening libraries of candidate bioactive agents, for example, nucleic acids and peptides, in cells using an regulatable expression system to enrich for a subpopulation of cells having an altered phenotype due to the presence of a candidate bioactive agent.